Clinical trials show targeted kinase inhibitors provide high response rates in children with refractory histiocytic disorders ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

Gedatolisib is approved in combination with fulvestrant, with or without palbociclib ...

ThalassaX Therapeutics United States Ltd today announced that the first patient has been successfully dosed in the U.S. Phase I clinical trial of CS231295, a next-generation brain-penetrant Aurora B ...

Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by attaching phosphate groups to other proteins. When these switches are stuck in the ...

Kinases are crucial to many signaling pathways, and when they don't work properly, the consequences can lead to problems, including cancer, immune diseases, and neurological disorders. But there are ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...

Eleven new molecular drug targets receive approval in 2025, expanding treatment options for rare diseases, cancer, and infectious diseases.